[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100614962":3},{"organization":4,"armGroups":7,"interventions":27,"overallOfficials":33,"centralContacts":34,"locations":43,"responsibleParty":57,"collaborators":33,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":33,"eligibilityCriteria":67,"healthyVolunteers":63,"sex":68,"minAge":69,"maxAge":33,"enrollmentInfo":70,"targetDuration":33,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":33,"overallStatus":80,"whyStopped":33,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Tanta University","OTHER",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"frusemide","ACTIVE_COMPARATOR","The furosemide group will receive 40 mg furosemide in 4 ml of 0.9% saline, administered \u002F6 hours for 7 days",[13],"Drug: nebulization",{"label":15,"type":10,"description":16,"interventionNames":17},"heparin","The heparin group will receive inhaled unfractionated heparin at a dose of 10,000 in 4 ml of 0.9% saline IU\u002F6 h daily for 7 days via ventilator circuit.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"hypertonic saline","This group will receive inhaled hypertonic saline 3% in a dose of 4ml \u002F6 h daily for 7 days.",[13],{"label":23,"type":24,"description":25,"interventionNames":26},"control","PLACEBO_COMPARATOR","This group will receive inhaled normal saline 0.9 % in a dose of 4ml \u002F6 h daily for 7 days.",[13],[28],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"DRUG","nebulization","Study solutions will be administered via a vibrating mesh nebulizer (Aerogen® Pro, Aerogen Ltd, Ireland) placed at the Y-piece of the ventilator circuit, proximal to the patient. The nebulizer will be used with its specific T-piece adapter. The nebulizer will be placed at the Y-piece (proximal to the patient), between the endotracheal tube and the circuit. To optimize aerosol delivery, a standardized nebulization protocol will be followed. For the 30-minute duration of each treatment, the ventilator will be set to Volume Control or Assist-Control mode with a constant inspiratory flow of 40-50 L\u002Fmin, an inspiratory-to-expiratory ratio of 1:3, and an end-inspiratory pause of 0.5 seconds. The heated humidifier will be turned off 15 minutes before and bypassed during the nebulization period. Immediately after the 30-minute nebulization is complete, the humidification chamber will be reconnected, and the heated humidifier will be turned back on.",[23,9,15,19],null,[35,40],{"name":36,"role":37,"phone":38,"phoneExt":33,"email":39},"tarek AH Mostafa","CONTACT","01003591332","dr.tarek311@yahoo.com",{"name":41,"role":37,"phone":33,"phoneExt":33,"email":42},"sameh Ahmed","samehabdelkhalik1982@gmail.com",[44],{"facility":45,"status":33,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":33},"Faculty of medicine, Tanta university","Tanta","El Gharbyia","31111","Egypt","EG",{"type":52,"coordinates":53},"Point",[54,55],31.00192,30.78847,{"lat":55,"lon":54},{"type":58,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":33,"oldOrganization":33},"PRINCIPAL_INVESTIGATOR","tarek abdel hay mostafa","principle investigator","100614962","nebulized-furosemide-heparin-hypertonic-saline-in-mechanically-ventilated-acute-respiratory-distress-syndrome-adult-patients-100614962",false,"NCT07286409","Nebulized Furosemide, Heparin, Hypertonic Saline in Mechanically Ventilated Acute Respiratory Distress Syndrome Adult Patients","Nebulized Furosemide, Heparin, Hypertonic Saline in Mechanically Ventilated Acute Respiratory Distress Syndrome Adult Patients: A Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Adult patients (≥18 years)\n* ICU admission, mechanical ventilation for \\\u003C 7 days\n* ARDS diagnosed within 24 hours per the Berlin Definition, which includes Chest x-ray showing bilateral opacities, not fully explained by effusions, lung collapse; Respiratory failure not fully explained by cardiac failure or fluid overload, and exclusion of hydrostatic edema (by echocardiography);\n* Oxygenation and ventilator settings matching one of the three categories of ARDS: Mild: 200 mmHg \\\u003C PaO2\u002FFIO2 ≤ 300 mmHg with positive end-expiratory pressure (PEEP) or continuous positive airway pressure (CPAP) ≥ 5 cm H2O. Moderate: 100 mm Hg \\\u003C PaO2\u002FFIO2 ≤ 200 mm Hg with PEEP ≥ 5 cm H2O. Severe: PaO2\u002FFIO2 ≤ 100 mm Hg with PEEP ≥ 5 cm H2O.\n\nExclusion Criteria:\n\n* 1- Pregnant Patient. 2- Refusal to participate in the trial by the patient's guardian. 3- Known allergy to furosemide or heparin. 4- Active major bleeding, recent intracranial hemorrhage 5- End-stage renal disease 6- Severe chronic liver disease. 7- Uncontrolled shock (e.g., high vasopressor doses). 8- Advanced directives limiting care (e.g., do-not-resuscitate orders), which could affect mortality outcomes.\n\n  9- Body Mass Index (BMI) \\> 40 or severe obesity, which can severely impact lung mechanics and confound results.\n\n  10- Electrolyte imbalance","ALL","18 Years",{"count":71,"type":72},344,"ESTIMATED","INTERVENTIONAL",[75],"NA","There are no specific drugs or therapies available to directly treat\u002Fprevent ARDS. Mechanical ventilation with an aim to minimize Ventilator Induced Lung Injury (VILI) and management of refractory hypoxemia are the keystones in supportive management of ARDS.",[78,79],"Respiratory Distress Syndrome","Mechanical Ventilation Complication","NOT_YET_RECRUITING","2025-12-02",{"date":83,"type":84},"2025-12-16","ACTUAL",{"date":86,"type":72},"2026-01",{"date":88,"type":72},"2027-01",{"name":5,"class":6},1]